Your Heart Plan After Preeclampsia

Preeclampsia is a cardiovascular warning, roughly doubling a woman’s future risk of heart disease and stroke. The standard obstetric follow-up does not include a cardiovascular plan. Most women who had preeclampsia are discharged with instructions about blood pressure monitoring for a few weeks postpartum, and then nothing, no follow-up timeline, no risk conversation, no referral. The pregnancy closes, and the cardiovascular signal it sent is filed with it. This article is the plan that should have been given at discharge, and it begins with why preeclampsia is a permanent cardiovascular variable, not a closed chapter.

The Mechanism

Preeclampsia is not simply high blood pressure during pregnancy. It is a systemic endothelial disorder in which the placenta, due to abnormal implantation and inadequate remodeling of the spiral arteries, releases factors that cause widespread vascular dysfunction in the mother. The endothelium, the single-cell lining of all blood vessels, loses its normal regulatory capacity: it becomes less able to produce nitric oxide, more prone to promoting vasoconstriction, and more permeable to proteins. That is why preeclampsia produces not just hypertension but proteinuria, edema, and in severe cases, end-organ damage to the liver, kidneys, and brain.

The critical question is why this endothelial dysfunction matters after delivery, when the placenta has been removed and blood pressure has often normalized. The answer is that the episode of preeclampsia does not leave the endothelium unchanged. It reveals a pre-existing susceptibility in the maternal vasculature, an underlying tendency toward endothelial dysfunction that the pregnancy stress test exposed but did not create. The vascular biology that allowed preeclampsia to develop was present before conception, and it persists after delivery.

Brosens and colleagues, among others, have described this framework: the placenta as a vascular stress test for the mother. A pregnancy complicated by preeclampsia is a failed stress test, revealing vascular biology that carries independent cardiovascular significance for the rest of the woman’s life. The endothelial susceptibility that permitted the disease to occur does not resolve with the placenta.

In the years following a preeclamptic pregnancy, this susceptibility manifests as accelerated risk of hypertension, coronary artery disease, heart failure, and stroke. The pathway includes persistent endothelial dysfunction, higher rates of dyslipidemia, and greater susceptibility to the vascular effects of subsequent risk factors. A woman with a history of preeclampsia who also develops hypertension or diabetes in her forties is not simply accumulating ordinary risk factors. She is accumulating them on a vascular substrate that is already more vulnerable than average.

The heart failure signal deserves particular attention. Preeclampsia is associated with postpartum cardiomyopathy in a subset of cases, and even in women who do not develop overt peripartum cardiomyopathy, subclinical left ventricular remodeling has been documented by echocardiographic studies in the weeks and months after preeclamptic pregnancies. Whether these subclinical changes contribute to later heart failure risk is under active investigation.

What the Evidence Shows

The epidemiological literature on preeclampsia and long-term cardiovascular risk is now extensive and consistent. The signal of approximately doubled cardiovascular risk comes from multiple independent cohorts across different populations.

Bellamy and colleagues published a systematic review and meta-analysis in the Lancet in 2007 that synthesized data from multiple studies following women with a history of preeclampsia. Their analysis found that preeclampsia was associated with approximately a twofold increase in the risk of heart disease and stroke over the subsequent 5 to 15 years, and roughly a threefold increase in hypertension. These estimates have been replicated and refined in subsequent studies but have not been substantially revised downward.

Cirillo and colleagues, reporting from a large Norwegian registry, extended the follow-up further and found that the cardiovascular mortality signal from a preeclamptic pregnancy persisted for decades. The absolute risk differences were most apparent in the decade following the affected pregnancy but did not disappear with time.

Mehta and colleagues, publishing in JACC, examined the association between preeclampsia and subsequent heart failure specifically, finding that women with a history of preeclampsia had materially higher rates of heart failure in later life than women whose pregnancies were uncomplicated. The mechanism proposed was the combination of persistent endothelial dysfunction and the subclinical left ventricular changes observed in the immediate postpartum period.

The ARIC study (Atherosclerosis Risk in Communities) contributed long-term follow-up showing that women who reported preeclampsia in their obstetric histories had higher coronary artery calcium scores in midlife than women without this history, even after adjusting for traditional cardiovascular risk factors. This is direct imaging evidence that preeclampsia leaves a structural vascular mark.

The standard 10-year cardiovascular risk calculators, including the Pooled Cohort Equations used widely in clinical practice, do not include preeclampsia history as a variable. This is a known limitation. Multiple cardiology societies, including the American College of Cardiology and the American Heart Association, have published guidelines explicitly naming preeclampsia as a risk-enhancing factor that should be elicited and counted in cardiovascular risk assessment when the standard calculator result is borderline or uncertain. The practical implication is that a woman whose 10-year risk calculator returns a number that seems low may have a true risk that is substantially higher once her obstetric history is factored in.

Fraser and colleagues, in a large UK cohort study published in BMJ, confirmed that the association between preeclampsia and later cardiovascular disease persisted regardless of subsequent pregnancy outcomes, meaning that a woman who goes on to have uncomplicated pregnancies after her preeclamptic one does not lose the elevated risk signal. The biology revealed by the first pregnancy continues to carry weight.

The risk also stratifies by severity. Women who had severe preeclampsia, defined by features including very high blood pressure, renal involvement, thrombocytopenia, or early onset before 34 weeks, carry higher subsequent cardiovascular risk than those with mild or late-onset preeclampsia. Ananth and colleagues, analyzing population-level data, found that early-onset preeclampsia was associated with the highest subsequent coronary risk, consistent with the principle that more severe placental dysfunction reflects more significant underlying maternal vascular pathology.

Lundberg and colleagues, publishing from Swedish registry data with decades of follow-up, found that the elevated cardiovascular mortality risk from preeclampsia remained statistically significant even 30 to 40 years after the affected pregnancy. This is a lifetime risk modifier, not a transient one, and the management response should match that duration.

Importantly, the evidence for what actually reduces the elevated risk after preeclampsia is thinner than the evidence that the risk exists. No randomized trial has been conducted specifically in women with preeclampsia history to test whether standard cardiovascular prevention measures reduce events in this population at rates that exceed what would be expected from their application in general populations. The elevated risk is well-established. The magnitude of risk reduction from specific interventions in this specific population is extrapolated from general cardiovascular prevention evidence rather than tested directly in preeclampsia survivors. 4 / Promising That does not argue against the prevention plan; it argues for clarity about what is known and what is inferred.

The cardiovascular risk from preeclampsia is also not limited to the classic endpoints of heart attack and stroke. George and colleagues, analyzing US hospitalization data, documented that women with a history of preeclampsia had substantially elevated rates of hospitalization for heart failure in the decade following their affected pregnancies, particularly heart failure with preserved ejection fraction. This type of heart failure, in which the heart muscle pumps normally but the ventricle is stiff and fills poorly, is the predominant form in women and is driven in part by the endothelial and vascular stiffness that preeclampsia both reflects and amplifies. Standard heart disease risk assessment does not ask about preeclampsia; standard heart failure screening does not begin until symptoms appear. This is precisely the gap that a deliberate post-preeclampsia plan is designed to fill.

Stroke risk is a separate and substantial concern. The ARIC data and multiple European registry analyses have shown that ischemic stroke risk is elevated in women with preeclampsia history at younger ages than the general population, consistent with the endothelial dysfunction framework. Blood pressure management is particularly important in this context because hypertension is both the most common downstream sequel of preeclampsia and one of the most modifiable stroke risk factors in women.

The Guideline Framework: Preeclampsia as a Formal Risk-Enhancing Factor

The cardiovascular medicine framework for adverse pregnancy outcomes has evolved substantially and now provides explicit guidance for incorporating preeclampsia history into risk management.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (Arnett et al., JACC 2019) explicitly names preeclampsia as a risk-enhancing factor — meaning it should be used to upgrade treatment intensity in women whose 10-year risk calculator places them in the borderline or intermediate range (7.5 to 20 percent 10-year risk). A woman at 8 percent 10-year risk whose standard calculator does not include her preeclampsia history may be undertreated. The guideline says preeclampsia history is grounds to reconsider that position. Statin initiation in a borderline-risk woman with preeclampsia history becomes more clearly justified under this framework than without it.

The 2021 AHA Scientific Statement on Cardiovascular Considerations in Caring for Pregnant and Postpartum Patients (Mehta LS et al., Circulation 2021) extended this framework to the postpartum period specifically. The statement recommends that all women with a history of a hypertensive disorder of pregnancy undergo blood pressure assessment within 7 to 10 days of delivery, formal cardiovascular risk factor screening within 1 to 2 years, and a dedicated cardiovascular risk discussion at the postpartum visit. The statement also recommends that obstetric providers communicate the cardiovascular risk implications directly to patients at discharge — not leave it to be discovered later in a primary care visit.

The European Society of Cardiology 2018 guidelines on cardiovascular disease in pregnancy classify preeclampsia as a risk factor for future cardiovascular disease and recommend annual blood pressure monitoring in this population. The ESC framework treats cardiovascular surveillance of women with prior preeclampsia as a routine component of preventive care.

The practical gap documented across all these guideline frameworks is the same: clinical practice has not caught up to guideline recommendation. Women who had preeclampsia are not systematically receiving the cardiovascular counseling these guidelines call for. The obstetric record does not transfer into primary care risk assessment in the structured way the guidelines envision. The woman most likely to benefit from this framework is the one who brings it to the clinical encounter herself, which is why the disclosure instruction in the action section below is not optional. 4 / Promising

What to Do This Week

1. Tell whoever manages your long-term health that you had preeclampsia and ask them to document it as a cardiovascular risk-enhancing factor, not as obstetric history. Use the specific language: “I had preeclampsia, and I understand it roughly doubles my long-term risk of heart disease and stroke. I want that counted in how we manage my cardiovascular risk.” If your clinician is unfamiliar with the cardiovascular implications, the AHA/ACC guidelines on cardiovascular risk assessment in women explicitly list preeclampsia as a risk enhancer.

2. Set up home blood pressure monitoring if you do not already have it. Check weekly rather than waiting for annual physicals. The hypertension that follows preeclampsia often develops gradually, and an annual check can miss a trajectory that a weekly check catches early.

3. Schedule lipid and glucose testing now, regardless of your age. Standard screening guidelines may not yet recommend these for your age group, but your preeclampsia history justifies earlier and more frequent monitoring. Ask specifically for ApoB alongside LDL.

4. Build heart-protective lifestyle habits as a long game starting now: a dietary pattern low in sodium and high in vegetables, legumes, and whole grains; consistent physical activity including both aerobic and resistance training; and sleep protection (7 to 8 hours, with attention to sleep quality). These are not hypothetically useful; they are the levers with the best evidence for reducing risk over decades.

5. If you are planning another pregnancy, disclose the preeclampsia history to your obstetric team early. Low-dose aspirin started before 16 weeks has evidence for reducing recurrent preeclampsia risk in women with a prior history, and your obstetric and cardiovascular risk both benefit from this being a planned, monitored pregnancy.

Preeclampsia hands a woman a warning about her cardiovascular future, and the plan after it is simple: monitor, manage, and start early. The blood pressure normalizes; the risk does not. Following that simple plan across decades, and ensuring the history is never filed away as closed obstetric record, is how a doubled risk becomes a managed one.